Sign In
Buy BCRX
$8.25
-0.0900 (-1.08%)
At Close: Jun 03, 2026
Why Fluidigm, Seelos Therapeutics And More Are Moving Today
11:27am, Friday, 22'nd Jan 2021
Fluidigm (NASDAQ: FLDM) shares are trading higher Friday after the company announced it received the CE-IVD mark for its Advanta Dx SARS-CoV-2 RT-PCR Assay. Fluidigm manufactures life science tools fo
BCRX Stock Price Increases Over 5% Pre-Market Today: Why It Happened
07:56am, Friday, 22'nd Jan 2021
The stock price of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is trading higher than 5% pre-market. This is why it happened.
BioCryst Announces Approval of ORLADEYO™ (berotralstat) in Japan for the Prophylactic Treatment of Hereditary Angioedema
07:00am, Friday, 22'nd Jan 2021
RESEARCH TRIANGLE PARK, N.C., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Ministry of Health, Labor and Welfare (MHLW) in Japan has granted
BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference
07:00am, Wednesday, 06'th Jan 2021
RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39th Annual J.P. Morgan Healthcare Co
BioCryst (BCRX) Provides Updates on Galidesivir, Shares Fall
11:18am, Wednesday, 23'rd Dec 2020
BioCryst (BCRX) will discontinue the study on its pipeline candidate, galidesivir, for treating patients with the novel coronavirus disease (COVID-19).
2 Ultra-High-Growth Healthcare Stocks That Are Just Getting Started
07:13am, Wednesday, 23'rd Dec 2020
Both stocks are in the early stage of a long-term growth trajectory.
Why BioCryst, VistaGen And Teladoc Are Moving Today
12:23pm, Tuesday, 22'nd Dec 2020
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher after Maxim raised its price target on the stock from $3 to $5. VistaGen Therapeutics is a biotechnology firm.
Why BioCryst Pharmaceuticals Stock Is Sinking Today
11:42am, Tuesday, 22'nd Dec 2020
Investors were disappointed by the biotech's COVID-19 clinical trial results.
BioCryst Provides Update on Galidesivir Program
07:00am, Tuesday, 22'nd Dec 2020
RESEARCH TRIANGLE PARK, N.C., Dec. 22, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that data from part 1 of a clinical trial of its broad-spectrum antiviral,
RESEARCH TRIANGLE PARK, N.C., Dec. 21, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that in a Phase 1 clinical trial with BCX9250, an oral activin receptor-li
5 Healthcare Stocks That Fared Well in 2020 Amid the Pandemic
12:47pm, Friday, 18'th Dec 2020
The U.S. healthcare sector emerged as one of the very few sectors that has been able to turn the misfortunes of COVID-19 pandemic to its advantage. The ongoing COVID-19 outbreak and an aging U.S. popu
BioCryst Announces U.S. Availability of ORLADEYO™ (berotralstat) for the Treatment of Hereditary Angioedema
07:00am, Wednesday, 16'th Dec 2020
—Direct to patient shipments of the first oral, once-daily prophylactic treatment underway through Optime Care —
BioCryst to Present at JMP Securities Hematology Summit
07:00am, Friday, 11'th Dec 2020
RESEARCH TRIANGLE PARK, N.C., Dec. 11, 2020 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the JMP Securities Hematology Summit, whi
BioCryst Pharmaceuticals: Orladeyo Approved, Financing Overhang Removed
06:13am, Thursday, 10'th Dec 2020
BioCryst received FDA approval for Orladeyo last week. The company quickly moved to raise cash and remove the financing overhang.
BioCryst Stock Price: $14 Target By HC Wainwright
02:46pm, Tuesday, 08'th Dec 2020
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) has received a price target increase from $13 to $14 by H.C. Wainwright.
